Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107331 | 0.88 | — | — | |
| SCHEMBL3577696 | 0.68 | MEN1 (0.32) | KDM4EMAPT | |
| SCHEMBL6168485 | 0.68 | PNMT (0.35) | — | |
| SCHEMBL105406 | 0.68 | KDM4E (0.32) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL2885325 | 0.67 | TSHR (0.50) | TSHR | |
| SCHEMBL688577 | 0.67 | NPC1 (0.50) | KDM4EMAPT | |
| SCHEMBL1451213 | 0.67 | NPC1 (0.50) | MAPTCA9 | |
| SCHEMBL9210549 | 0.67 | KDM4E (0.34) | KDM4EMAPT | |
| SCHEMBL871100 | 0.67 | ITGB2 (0.38) | MAPT | |
| SCHEMBL586947 | 0.67 | SIGMAR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 705 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-10207985-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2019-02-19 | — | — | US | claimed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | claimed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | claimed |
| EP-2421823-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-14 | — | — | EP | claimed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | claimed |
| EP-1648426-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2014-01-08 | — | — | EP | claimed |
| EP-1339663-B1 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| WO-2009006089-A2 | A2 ADENOSINE RECEPTOR AGONISTS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | claimed |
| EP-0314852-B1 | Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives | CIBA GEIGY AG (CH) | 1993-11-18 | — | — | EP | claimed |
| US-5262537-A | Treatment of nausea and vomiting | ANAQUEST, INC. (US) | 1993-11-16 | — | — | US | claimed |
| EP-0207563-B1 | A METHOD FOR CONTROLLING WEEDS | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-31 | — | — | EP | claimed |
| EP-0216483-B1 | THERMAL TRANSFER PRINTING | ZENECA LIMITED (GB) | 1990-04-11 | — | — | EP | claimed |
| EP-0289066-A1 | 1,5-Substituted 1H-imidazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-11-02 | — | — | EP | claimed |
| EP-0277384-A2 | 1H-imidazole-5-carboxylic acid derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-10 | — | — | EP | claimed |
| EP-0207563-A2 | A method for controlling weeds | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-01-07 | — | — | EP | claimed |
| US-4258192-A | SUSPRESSION OF THROMBOSIS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1981-03-24 | — | — | US | claimed |
| US-4201863-A | ANTICOAGULANTS | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1980-05-06 | — | — | US | claimed |
| EP-0008746-A1 | Alpha-(N-arylsulfonyl-L-argininamides, processes for their preparation and pharmaceutical compositions containing these substances | MITSUBISHI KASEI CORPORATION (JP) | 1980-03-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | TSHR 4163/4885SRC 1527/4885HTR2C 3523/4885 |
| US-10207985-B2 | Compounds | CYP1B1, DDT, CYP1A1 | TSHR 3997/4885SRC 1547/4885HTR2C 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.